Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
trusted medical experts at The Maxim Clinic
China GLP-1 Drugs Market Trends The growing rates of lifestyle-related diseases in China are increasing the use of GLP-1 drugs
I am not a doctor, nor have I tried many of these products, so I encourage you to consult with a physician before adding anything into your daily routine
The tool shows: Comparison cards : mechanism, evidence tier, FDA status, weight loss data, dosing, cost, pros, cons, and side effects Bar chart : average weight loss percentage from pivotal clinical trials Radar chart : multi-dimensional comparison across efficacy, evidence quality, convenience, tolerability, cost, and cardiovascular data Emerging research : next-generation compounds including BRP (Stanford's natural peptide), survodutide, orforglipron, and amycretin Understanding the data Each weight-loss figure traces to one specific trial: about 15% for semaglutide (STEP 1), up to 22.5% for tirzepatide (SURMOUNT-1), and 24.2% for retatrutide, only a phase 2 result
